In short: Falcon lands early adopters — and agentic AI reaches production. Q2 revenue +18% Y/Y to $928M ($23M beat) with non-GAAP EPS of $2.35 ($0.13 beat); subscription revenue +16% to $767M, and shares jumped after Veeva raised its full-year outlook. Veeva Falcon now has five early adopters, with first go-lives expected this year; Veeva also launched Falcon MLR for automated marketing-content review and acquired Copli — but "importantly, this is still early adoption rather than meaningful revenue contribution." Vault CRM had its best quarter yet, crossing 180 live customers from 150+ in Q1, with five top-20 biopharmas live and 12 top-20 commitments as of August; one top-20 customer "deployed Veeva's Agentic Call Report across its entire US field team, providing a more tangible example of AI moving from product roadmap to production." Momentum extends beyond CRM: Veeva Safety crossed 100 customers, Quality added 30+, and newer R&D products are "increasingly taking over growth from mature applications such as eTMF and QualityDocs." FY27 revenue guidance raised again to $3.682–$3.687B (from $3.635–$3.645B). Bottom Line: "Vault CRM remains the near-term growth engine, but Veeva's agentic-labor opportunity is starting to move beyond the concept stage." A disclosed author holding.
Veeva sells software built specifically for drug companies — the systems that manage clinical trials, regulatory documents, product-safety reporting and the sales reps who visit doctors. Because pharma is heavily regulated, this software has to be validated and audited, which makes it very hard to replace once installed and very hard for a generic competitor to enter.
Two different things happened this quarter, and it is worth keeping them apart. The first is Falcon, Veeva's attempt at "agentic labor" — AI that performs a whole job function rather than assisting a person doing it. Falcon has five early customers with the first live deployments due this year. Five is a pilot programme, and the newsletter says so plainly: this is early adoption, not revenue.
The second is the part that is already paying. Vault CRM — the system reps use in the field, which Veeva built to replace a Salesforce-based product it used to resell — crossed 180 live customers from 150-odd three months ago, with five of the twenty largest drug companies now running it and twelve committed. And one of those top-20 customers put Veeva's "Agentic Call Report" — AI that writes up a sales visit automatically — across its entire US field force. That is the difference between a pilot and production, and it is the strongest evidence in this issue that agentic AI is doing real work inside a real company. Growth is also broadening beyond CRM: the safety product passed 100 customers, and newer research products are taking over from the mature ones. Guidance was raised again and the stock rose. The author owns it. Analysis, not a recommendation.
In short: Q1 rev +16% to $883M; subscription +15% to $730M; Vault CRM crossed 150 live customers (80% win rate); raised FY27 guide, reiterated $6B by 2030. Launched Veeva Falcon — agentic "headless" labor: AI agents designed to fully replace specific job functions (clinical-trial documentation, safety-case triage) under a "models, agents, applications" (MAP) architecture. Uses Claude Code internally; says it will hire less as AI productivity scales.
Veeva makes the software that pharmaceutical and biotech companies run on — managing clinical trials, drug-safety records, and sales to doctors. Revenue grew a steady 16% and its newer CRM product crossed 150 customers, so the core business is healthy and management reaffirmed a path to $6 billion in revenue by 2030.
The interesting new bet is "Veeva Falcon," built around agentic labor. Most AI tools assist a human (autocomplete, draft, suggest). Falcon's agents are meant to fully replace a specific job function — running "headless" (no human at the keyboard) to do things like write clinical-trial documentation or triage drug-safety cases. In other words, Veeva is selling software that does the job, not software that helps someone do the job. Tellingly, Veeva uses Claude Code internally and says it will hire fewer people as AI lifts its own productivity — a company eating its own dog food. Neutral because it's early and the revenue impact is unproven, but the model is a notable shift.
Nothing matches this filter.
Verbatim excerpts from the public transcripts (auto-pulled at each mention's timestamp, lightly cleaned). Timestamps link into the video; "source page" opens that commentator's full analysis at this row. Click a mention's header line to expand it (one open at a time). For personal study — not investment advice.